W STRATEGIES, LLC for CALIFORNIA LIFE SCIENCES
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Medicare/Medicaid MMM
Education on the importance of maintaining the competitive elements of the Part D prescription drug program and to oppose efforts to impose mandatory government rebates in that program. P.L. 112-25 - The Budget Control Act of 2011 as it relates to proposals to impose mandatory rebates in the Part D program. P.L. 112-25 - The Budget Control Act of 2011 as it relates to proposals affecting reimbursement of Part B drugs.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DARREN WILLCOX | — |
Health Issues HCR
Promoted life sciences community and communicated economic and health benefits of the industry. FDA Reform Issues related to reform of the drug and device approval process. Educated staff about analysis of data related to the drug and device approval process at FDA. S.17 - Medical Device Access and Innovation Act. H.R. 436 - Protect Medical Device Innovation Act.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DARREN WILLCOX | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.